PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Wednesday, July 3, 2013

Ten tips when writing about clinical trials by Ruth Francis, BioMed Central.

Posted on 11:24 PM by Unknown
  1. Was this trial registered before it began? It should have been! So that we can scrutinise it and make sure negative results don’t get hidden.
  2. Is the primary outcome reported in the paper the same as the primary outcome specified in the protocol? If not, why not? Though researchers may publish their protocol in advance when registering a trial, not all registries require it.
  3. Look for other trials by this company, or group, or on this treatment and on registries: have these all been published? If not, then this report possibly represents a biased and cherry picked finding.
  4. ALWAYS mention who funded the trial – it matters. Whether some of the ethics committee people have some interest with the funding company.
  5. Look at whether the country where the work is done will benefit from the trial. Will they get the drug at a lower cost or not? Is it investing a disorder or disease that is a problem in that country.
  6. How many patients were on the trial, and how many were in each arm. Some trials can only have small patient groups, but others will need to study many more patients to draw the conclusions that may be being claimed.
  7. What was being compared? Was it drug vs placebo? Drug vs standard care? Drug with no control arm?
  8. Be precise about the sort of people or patients who benefited – was it just in advanced disease, people with a particular form of a disease? Contextualise how common these patients are in the bigger picture.
  9. Report natural frequencies as these are much more meaningful to both laypeople and experts: 13 people per 1000 experiencedx is clearer than 1.3% of people experienced x
  10. Avoid relative risks and try to paint the findings in meaningful terms. So if you say the drug improved survival by X% it’s hard to know quite what that means. If you wrote: people taking the drug lived four months longer on average, you’d be clearer. Best of all would be to say: patients taking the drug lived four months longer on average, which is two months longer than the control group.
http://www.alltrials.net/2013/the-challenges-for-journalists-writing-about-clinical-trials/
?utm_source=dlvr.it&utm_medium=twitter
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ▼  July (104)
      • Still a fantastic read
      • GlaxoChinaGate contd. - Nothing uniquely Chinese a...
      • Hope for the future
      • Slumdog clinical trials contd. - BMJ editorial: In...
      • Let the sunshine in
      • Hongbao - the red envelope
      • Sharing data from clinical trials: where we are an...
      • Pfizer Pleads Guilty, Pays $491 Million Over Rapam...
      • Caveat lector!
      • Now this is worrying
      • FDA toughens malaria drug labeling because sometim...
      • An addiction that is hard to break
      • GlaxoChinaGate contd. The case of Zhao Hongyan, th...
      • Perrigo buys Irish drug maker Elan in $8.6bn deal
      • 1boringoldman makes the case for data transparency
      • GSK investigation reveals something rotten - China...
      • The Glaxo-China Bribery Scandal: A New Policeman W...
      • UK pharma shows signs of dangerous addiction
      • Paul Krugman: China’s economy has hit its Great Wall
      • Class-action suit over Pfizer Canada's anti-smokin...
      • GlaxoChinaGate contd. - Reilly to return to China!
      • China state media says 18 more detained in GSK probe
      • Bergstroem's mobilising memo
      • GlaxoChinaGate contd.- The World of Suzie Wang
      • GlaxoChinaGate contd. - is this the payoff?
      • Big Pharma’s data sharing principles “weak and fil...
      • GlaxoChinaGate contd. - the Chinese police reveal ...
      • Banks and Big Pharmas hire private eyes who break ...
      • Pharma industry downplays lobbyism with patient gr...
      • Meanwhile, in other GSK news...
      • GlaxoChinaGate contd. Witty may not be forthcoming...
      • The World According to Monsanto
      • Patient groups commit to transparency after leaked...
      • GSK's China crisis: questions for Witty that need ...
      • More Astra staff held in China as GSK crisis deepens
      • Antimalarial Drug Linked to Sgt. Robert Bales Mass...
      • Drug Research in China Falls Under a Cloud
      • How to lower Big Pharma's drug prices the Chinese way
      • It's a strange old world
      • A message from AllTrials.net
      • GSK's China Crisis spreads
      • Files Suggest a Graft Case in China May Expand - NYT
      • AllTrials contd. Which patient groups are in Big P...
      • Healthcare in China: GSK claims prompt crackdown o...
      • More on Peter Humphrey, MD of ChinaWhys
      • GSK boss to address China scandal at quarterly res...
      • Killing the chicken to scare the monkey
      • GlaxoSmithKline briefs Serious Fraud Office over C...
      • Comment: China crisis growing for troubled Glaxo
      • China - getting in is easier than getting out!
      • GlaxoSmithKline's China crisis: why it changes the...
      • GlaxoSmithKline rushes executives to China to hand...
      • GSK chief Andrew Witty set to admit China 'scam’
      • Can Merck Finally Get Past the Vioxx Scandal?
      • NHS could save £84m using cheaper drug to prevent ...
      • Worth every penny
      • China - Now UCB get a visit
      • Johnson and Johnson Settles Suit Alleging Manageme...
      • GSK China's General Manager Mark Reilly Presents O...
      • Pharma Companies Must End Secret Gifts To Doctors ...
      • Eli Lilly to Freeze Employee Base Pay Ahead of Gen...
      • Latest MTRAC reviews
      • China bars Glaxo finance director from leaving cou...
      • GSK's Andrew Witty's new role in China
      • Four Drugmakers Face China Probes as Glaxo Woes Widen
      • A fish starts to rot from the head. After GSK, who...
      • Sexual Favors Spur Glaxo’s $1.5 Billion China Sale...
      • First GSK denied......
      • GSK China - Watch the confession
      • Anyone know where GSK's Mark Reilly is?
      • AZ - Exit the gas man
      • Do Clinical Trials Work? - NYT
      • David Healy vs AbbVie - A good medicine is a chemi...
      • UK NHS hit for millions by overcharging ‘scam’ - ...
      • Chinese clinical trials probed
      • Did Big Pharma team up to kill British Columbia's ...
      • Japan vows action over claims of fabricated drug data
      • Stopping Big Pharma From Using New .pharmacy Domai...
      • Our medical schools must not become shills for big...
      • GSK vs PSB
      • China security ministry says GSK executives confes...
      • Merck 'Evergreens' Off-Patent Lipitor By Creating ...
      • Wolfe Attack!
      • Drug Rep$
      • Are Clinical Trial Data Shared Sufficiently Today?
      • Stop blanket animal antibiotics now - before it's ...
      • Castellani vs Goldacre
      • Recent €23 Million Biotech IPO Relied Heavily On Q...
      • Australia targets Nurofen
      • New bribery allegations hit GlaxoSmithKline in China:
      • GSK's Dierdre P. Connelly makes a promise
      • Gouging contd. - How to make a $300 drug cost $30,...
      • "It may have been Roaccutane"
      • Ghost- and Guest-Authored Pharmaceutical Industry-...
      • Drs. Oz & Roizen's Tip of the Day: What's up with ...
      • Tchotchke War Looms
      • Ten tips when writing about clinical trials by Rut...
      • Pfizer and Merck
      • An interesting case
      • Pharma "a prime target" of govt health cuts in 201...
      • Sanofi to cut 207 R&D jobs in latest French reshuffle
      • Clot Wars contd.
      • GlaxoSmithKline Probe in China Follows Drug Safety...
      • Merck's Mess
    • ►  June (81)
    • ►  May (5)
Powered by Blogger.